검색
Valneva SE
VALN관심 목록에 추가
5.680USD
-0.260-4.38%
종가 05/15, 16:00（ET）시세는 15분 지연됩니다
545.56M시가총액
손실P/E TTM
자세한 내용은 Valneva SE 회사
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE 정보
종목 코드 VALN
회사 이름Valneva SE
상장일Jun 28, 2007
CEOLingelbach (Thomas)
직원 수- -
유형Depository Receipt
회계 연도 종료Jun 28
주소6, Rue Alain Bombard
도시SAINT-HERBLAIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가France
우편 번호44800
전화33228073710
웹사이트https://valneva.com/
종목 코드 VALN
상장일Jun 28, 2007
CEOLingelbach (Thomas)
Valneva SE의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
수익 분석
통화: USD마지막 업데이트: Mon, Apr 6
통화: USD마지막 업데이트: Mon, Apr 6
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
IXIARO
98.42M
56.35%
DUKORAL
31.91M
18.27%
Third party products
19.16M
10.97%
R&D
9.98M
5.72%
IXCHIQ
8.42M
4.82%
기타
6.77M
3.87%
지역별USD
이름
수익
비율
United States
53.61M
30.69%
Canada
30.13M
17.25%
Germany
17.47M
10.00%
France
14.67M
8.40%
Nordics
13.90M
7.96%
기타
44.89M
25.70%
사업별
지역별
사업별USD
이름
수익
비율
IXIARO
98.42M
56.35%
DUKORAL
31.91M
18.27%
Third party products
19.16M
10.97%
R&D
9.98M
5.72%
IXCHIQ
8.42M
4.82%
기타
6.77M
3.87%
주식 보유 통계
마지막 업데이트: Thu, May 7
마지막 업데이트: Thu, May 7
주주
주주 유형
주주
주주
비율
Novo Holdings A/S
2.43%
Frazier Life Sciences Management, L.P.
2.42%
General American Investors Company, Inc.
0.37%
Wells Fargo Advisors
0.08%
Morgan Stanley & Co. International Plc
0.03%
기타
94.66%
주주
주주
비율
Novo Holdings A/S
2.43%
Frazier Life Sciences Management, L.P.
2.42%
General American Investors Company, Inc.
0.37%
Wells Fargo Advisors
0.08%
Morgan Stanley & Co. International Plc
0.03%
기타
94.66%
주주 유형
주주
비율
Venture Capital
2.44%
Private Equity
2.42%
Investment Advisor
0.43%
Research Firm
0.17%
Hedge Fund
0.02%
기타
94.51%
기관 주식 보유
마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
36
5.21M
5.50%
-309.16K
2025Q4
32
5.27M
6.14%
+505.55K
2025Q3
30
4.53M
5.58%
+3.61M
2025Q2
25
665.50K
0.82%
-300.83K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Novo Holdings A/S
2.31M
2.66%
-40.00K
-1.71%
Dec 31, 2025
Frazier Life Sciences Management, L.P.
2.29M
2.64%
--
--
Dec 31, 2025
General American Investors Company, Inc.
354.36K
0.41%
--
--
Dec 31, 2025
Wells Fargo Advisors
123.46K
0.14%
-30.53K
-19.82%
Dec 31, 2025
Morgan Stanley & Co. International Plc
32.26K
0.04%
+9.49K
+41.70%
Dec 31, 2025
Ironwood Investment Management, LLC
25.14K
0.03%
--
--
Dec 31, 2025
Citadel Advisors LLC
23.49K
0.03%
+7.08K
+43.17%
Dec 31, 2025
Morgan Stanley Smith Barney LLC
10.70K
0.01%
+500.00
+4.90%
Dec 31, 2025
XTX Markets LLC
10.63K
0.01%
+10.63K
--
Dec 31, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
